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In patients with advanced soft tissue sarcoma treated with chemotherapy, WHO performance status, 2 
histologic subtype and histologic grade are known prognostic factors. Although the difference between 3 
the subgroups: locally advanced disease only, metastatic disease only and both local and metastatic 4 
disease is easily made, its prognostic relevance is thus far unknown. The aim of this EORTC database 5 
study was to study the difference in prognosis between these subgroups in patients receiving first line 6 
chemotherapy for advanced soft tissue sarcoma. 7 
Methods 8 
A retrospective database analysis was performed on 2473 patients receiving first line chemotherapy 9 
for advanced soft tissue sarcoma from 12 EORTC sarcoma trials in order to establish the difference in 10 
prognosis for the three subgroups. Endpoints were overall survival, progression-free survival and 11 
overall response rate. Factors studied were age, sex, histologic subtype, histologic grade, WHO 12 
performance status, treatment and time since initial diagnosis. 13 
Results 14 
Overall survival differed significantly between patients with locally advanced disease only, with 15 
metastatic disease only and with both locally advanced and metastatic disease with a median overall 16 
survival of 15.4, 12.9 and 10.6 months respectively. Similar differences were seen for progression-free 17 
survival (5.8, 4.3 and 3.2 months respectively).  18 
Conclusion 19 
This large retrospective database study shows that patients with advanced soft tissue sarcomas 20 
treated with first line chemotherapy with locally advanced disease, metastatic disease and both local 21 
and metastatic disease have different outcomes. This should be accounted for in future study design, 22 
interpretation and comparison of study results and daily practice.  23 
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Soft tissue sarcomas (STS) are a rare group of tumours consisting of more than 70 3 
histological different subtypes.(1) For the treatment of most subtypes, doxorubicin alone or in 4 
combination remains first line treatment with e.g. pazopanib and trabectedin as second line options.(2-5 
5) For anthracycline and ifosfamide based treatments, prognostic and predictive factors were 6 
established.(6-9) These studies identified response to chemotherapy, WHO performance score, 7 
histological subtype and time since initial diagnosis to be prognostic for overall survival (OS) in 8 
STS.(6-9) One of these studies also identified a difference in OS between patients with locally 9 
advanced disease (LAD) and patients with distant metastases (DM), favouring the first subgroup when 10 
treated with first-line ifosfamide therapy.(6) 11 
Although the difference between LAD and DM is easily made, no study investigated whether 12 
differences in outcome and response exist between these two subgroups, which could make them 13 
factors of prognostic relevance. The identification of prognostic factors is necessary for patient care 14 
and design of clinical trials. The aim of this study is to investigate whether important differences exist 15 
in OS, progression free survival (PFS) and response rate (ORR) between the different disease 16 
subgroups and is an exploratory analysis of the prognostic factors for OS, PFS and ORR in patients 17 
with STS and either LAD or DM at the moment of inclusion in a first line chemotherapy study of the 18 
European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone 19 





The EORTC-STBSG database contains data of 3708 patients from 15 EORTC advanced STS 3 
trials considering first line treatment.(4, 5, 10-22) Supplementary table 1 and 2 describe the different 4 
studies and the number of patients included in this study. From this database patients were excluded 5 
who had no documentation of lesions at trial entry, who had no survival data available, who were 6 
treated with a CYVADIC (cyclophosphamide/vincristine/doxorubicin/dacarbazine) regimen (EORTC-7 
study 62761)(10) or docetaxel (1 arm of 62941)(17), who had prior (adjuvant or palliative) 8 
chemotherapy, for whom not enough information was available to distinguish primary from metastatic 9 
disease (62883 and 62901)(14, 15), or who were diagnosed with gastrointestinal stromal tumour 10 
(GIST) or an ineligible tumour, being not STS.  11 
Patients were grouped in a group with local disease only (LAD), a group with metastatic 12 
disease only (DM) and both locally advanced and metastatic disease. LAD was defined either as 13 
locally advanced disease not amenable to surgery or locally recurrent disease. DM only was defined 14 
as distant metastatic disease without evidence for local disease. Patients in the group with both had 15 
local disease and distant metastatic disease at study inclusion. 16 
Endpoints 17 
Study endpoints were OS, PFS and ORR to therapy. OS was computed from the date of 18 
randomization or the date of prospective registration (nonrandomized trials) to date of death. Patients 19 
alive at last follow up were censored. PFS was defined as time interval between date of randomization 20 
or prospective registration and date of first documented progression or death, whichever comes first. 21 
ORR to chemotherapy was evaluated according to WHO or RECIST criteria depending on the 22 
study.(23-25) In this study it was analysed as binary variable, i.e. complete response and partial 23 
response are considered response and stable disease, progression or non-evaluable assessment 24 
were considered failures. 25 




Demographic data included were age, sex and performance status before the start of 1 
chemotherapy. Performance status was measured on the WHO scale. Variables related to the history 2 
of the sarcoma were the site of the primary tumour, the use of prior radiotherapy and/or prior surgery, 3 
and time since first diagnosis of sarcoma. Because information on prior radiotherapy or prior surgery 4 
was not collected in the more recent trials it has not been included in the univariate and multivariate 5 
prognostic factor analysis to reduce the loss of data due to missing information. In most of the included 6 
studies patients had to have progression in the six months before study inclusion or have had to a 7 
histological grade of at least 2 or intermediate. Treatment was aggregated in 4 categories: 8 
anthracyclines alone (doxorubicin, epirubicin), ifosfamide alone, combination of anthracyclines and 9 
ifosfamide and other (brostallicin and trabectedin).  10 
The way histological grade and histological subtype were used was earlier described in a 11 
study by our group.(6)  Histological subtype was aggregated into the 4 most common groups: synovial 12 
sarcoma, leiomyosarcoma, liposarcoma and others. If both a local and central histological subtype 13 
were available, the central diagnosis was used. Twenty-five percent of patients had a discrepancy 14 
between the central and local diagnosis. If only a local diagnosis was available this diagnosis was 15 
used.  16 
Statistics 17 
Categorical data were summarized by frequencies and percentages, continuous covariates 18 
were summarized by median, interquartile range and overall range and were presented according to 19 
the three different groups. The characteristics were compared with a χ2-test for categorical variables 20 
and a (non-parametric) Kruskal Wallis test for the continuous variables.  21 
The potential prognostic value of all factors was investigated by univariate analysis, using 22 
univariate Cox or logistic regression models according to outcome. The prognostic value of the factors 23 
was subsequently assessed in a multivariate model, using stepwise selection. All models were 24 
stratified by treatment for heterogeneity that may be introduced by merging data from several clinical 25 
trials. Statistical significance was set at 0.05 for all analyses.  26 
To reduce the loss of a considerable amount of information for the multivariate analysis due to 27 
a substantial amount of missing data for grade and site of primary tumour, the value “missing” was a 28 
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separate category in all these models. Sensitivity analyses were performed to study the impact of this 1 
approach on the final interpretation of the models.  2 
In addition, the analyses were repeated for only those patients included in studies after 1999 3 
to account for the diagnosis of GIST, improved radiology techniques and improved treatment 4 
regimens, which is included in the supplementary materials. 5 





In total, 2473 patients from 12 trials were included in this study, which were separated in 3 3 
subgroups: LAD (329 patients), DM (1202 patients) and patients with both LAD and DM (942 patients). 4 
(Supplementary figure 1) Table 1 shows the characteristics of the three subgroups.  5 
Median follow-up in years, as determined by the reverse Kaplan-Meier estimates, was 3.6 6 
years (interquartile range 2.2-6.4) for LAD, 3.2 years (2.1-4.9) for DM, and 3.6 years (2.1-6.4) for 7 
patients with both.  8 
Differences in survival and ORR 9 
Compared to LAD, patients with DM had a worse prognosis (hazard ratio (HR) 1.25 (95% CI 10 
1.08-1.45)) and patients with both LAD and DM had the worst (HR 1.59 (1.37-1.84)) (P<0.001). 11 
(Figure 1A) Median OS was 15.4 (95% CI 13.0-16.9), 12.9 (12.4-13.9) and 10.6 months (9.8-11.3) 12 
respectively. Of all patients 94.5% showed disease progression during follow-up. For PFS the same 13 
differences in survival were seen, with HR of 1.40 (1.23-1.59) for DM and 1.58 (1.38-1.81) for both 14 
LAD and DM (P<0.001). (Figure 1B) Median PFS was 5.8 (95% CI 4.4-6.5), 4.3 (3.9-4.7) and 3.2 15 
months (2.9-3.5) respectively.  16 
ORR differed among the three groups with the lowest ORR in patients with both LAD and DM 17 
(p=0.003). (Table 2) 18 
Prognostic factors for OS 19 
Table 3 shows the results of the univariate analysis. Multivariate analyses for LAD identified good 20 
performance status, histological subtype (synovial and liposarcoma), time since initial diagnosis (being 21 
not 6-12 months) and extremity site of tumour as favourable prognostic factors (table 4). For DM, the 22 
favourable prognostic factors were good performance status, histological subtype (synovial and 23 
liposarcoma) and long interval since initial diagnosis (table 4). Favourable prognostic factors for OS for 24 
patients with both LAD and DM were good performance status, female gender, younger age, lower 25 
grade, extremity site of primary tumour and long interval since initial diagnosis (table 4).Prognostic 26 
factors for PFS 27 
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Table 5 shows the results of the univariate analysis. Multivariate analyses for LAD identified 1 
good performance status and time since initial diagnosis (being not 6-12 months) as favourable 2 
prognostic factors (table 6). For DM, the favourable prognostic factors were good performance status, 3 
histological subtype (synovial and liposarcoma) and long time since initial diagnosis (table 6). 4 
Favourable prognostic factors for PFS for patients with both LAD and DM were good performance 5 
status, histological subtype (synovial and liposarcoma) and lower grade (table 6). 6 
Prognostic factors for overall response 7 
Results of the univariate analysis and multivariate analysis for prognostic factors for ORR are shown in 8 
table 7 and 8. 9 




This study is the first showing that for all frontline treatments in locally advanced and/or 2 
metastatic soft tissue sarcomas OS, PFS and ORR outcomes differ according to disease subgroup. 3 
This difference should be accounted for in daily practice and when designing and interpreting clinical 4 
trials. We also established prognostic factors for OS, PFS and ORR in these different disease 5 
subgroups and important differences in prognostic factors between these disease subgroups were 6 
identified, which underlines the importance of accounting for the different disease subgroups. Patients 7 
with LAD had a better prognosis compared to both other groups. This difference may be explained by 8 
additional treatment with either surgery or radiotherapy in the locally advanced setting. No data on 9 
post-chemotherapy treatment was available in the study database used for this project and so we 10 
cannot provide evidence for this statement. The difference in survival between the different disease 11 
subgroups stresses the importance of stratification for disease subgroup in future trials.  12 
In line with this observation, locally advanced tumours of the extremity had a better OS than 13 
other tumour sites, because these are more accessible to surgery and radiotherapy with relatively low 14 
morbidity. This was also found recently in an Indian study which showed that patients with extremity 15 
tumours and patients with multimodality treatment had a favourable prognosis, suggesting that the 16 
possibility of aggressive treatment of the primary tumour localization may result in a better 17 
survival.(26) Tumour site is also a known prognostic factor in surgically treated non-metastatic 18 
sarcoma patients.(27) Time since initial diagnosis behaves differently as prognostic factor between 19 
patients with LAD (both a very short time and a very long time from initial diagnosis were associated 20 
with a favourable prognosis) and both the other groups (only a long time interval from initial diagnosis 21 
having a favourable diagnosis). This could be because aggressive tumours tend to respond fast to 22 
chemotherapy and so become amenable to surgical therapy as a local treatment, which could prolong 23 
the OS. This was already shown in a previous database study of our group.(7) In the metastatic setting 24 
surgery usually is not an option and aggressive tumours will progress early. The fact that high 25 
histological grade is a favourable prognostic factor for ORR in patients with both LAD and DM 26 
supports this hypothesis. On the other hand, very early relapse, i.e. recurrence within 6 months after 27 
resection, could be caused by incomplete surgery, which would result in a group with mixed biology, 28 
and early relapse, i.e. recurrence between 6 and 12 months after resection, is caused mainly by bad 29 
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biology. Because bad biology will lead to more rapidly progression compared to the mixed biology of 1 
the very early relapse group. This could also explain the difference in prognosis. 2 
As in earlier studies for STS and other tumours performance status, histologic subtype and 3 
time since initial diagnosis were prognostic factors for OS.(8, 9, 28-30) Remarkably, in the multivariate 4 
analyses histologic subtype was no longer prognostic for patients with both LAD and DM. As was 5 
already mentioned in the methods section, histopathologic diagnosis was in approximately 25% of the 6 
patients different between local and central review. This difficulty with correctly classifying sarcomas 7 
could result in the differences in outcome between the various studies when studying histological 8 
subtype as prognostic factor. Histologic grade, also a known prognostic factor, was not identified as 9 
prognostic factor for OS in patients with LAD and dropped out in the multivariate model of metastatic 10 
disease, however this could be due to an underpowered comparison due to the lower number of 11 
patients in this group.(8) In general, synovial and liposarcoma are known to be sarcomas with a 12 
relatively good prognosis.(31) For both patients with LAD and patients with both LAD and DM, age and 13 
gender were both prognostic factors for patients with both local and metastatic disease compared to 14 
the two other groups. The difference in prognosis between sexes was found previously in other studies 15 
and it was hypothesized that it was caused by differences in pharmacokinetics of cytostatic drugs of 16 
amongst other cyclophosphamide and doxorubicin, with a decreased metabolism in women and so a 17 
higher drug exposure.(32) On the other hand the difference could be explained by the high grade 18 
undifferentiated uterine sarcomas, which of course only occur in women and have a very poor 19 
prognosis.(33) However, whether these two explanations are the full explanation is questionable 20 
because it was not a prognostic factor for OS in patients with LAD or DM and it was not a prognostic 21 
factor for PFS and ORR. For PFS the known risk factors performance status, histological subtype, 22 
time since initial diagnosis and grade were identified as prognostic factors. No new prognostic factors 23 
were identified. The same difference for time since initial diagnosis was found as for OS.  Grade was 24 
only prognostic for patients with both LAD and DM and such that a higher grade was associated with a 25 
worse PFS.(8) For LAD no prognostic factors for ORR were identified in contrast to patients with DM 26 
and patients with both LAD and DM. For patients with DM histology and site of primary tumour were 27 
identified. The role of primary tumour site may relate to later diagnosis and bulkier disease at 28 
presentation for non-extremity disease. As earlier mentioned low grade and high grade had a 29 
favourable prognosis compared to intermediate grade tumours for ORR in patients with both LAD and 30 
12 
 
DM. High histologic grade was previously found to be prognostic, but the finding that low histologic 1 
grade was associated with a better overall response rate is surprising.(7) As grading of sarcomas is 2 
difficult and it was an inclusion criterion for the studies to be progressive within 6 months before study 3 
inclusion, it could be that the included grade I sarcomas had a more aggressive behaviour like grade 4 
III tumours.  5 
The results of this retrospective study should be interpreted with care. First, the database 6 
contains studies over 32 years. In this time, treatment has changed and supportive measurements 7 
have improved. These could influence the prognostic factors. Also, the histologic subtypes of STS 8 
have changed over the years. High incident subtypes like malignant fibrous histiocytoma no longer 9 
exist in the current WHO classification.(1) Also new subtypes were identified during these years, like 10 
GIST often diagnosed as leiomyosarcoma before 2000.(34-36) An additional subgroup analysis with 11 
only those patients included in studies after 1999 was done to account for these changes. Although 12 
this subgroup analysis was hampered by the reduced number of patients, it resulted in comparable 13 
outcomes. (Supplementary data: additional subgroup analysis)   14 
In the future, treatment will be more and more histological subtype and molecular driver 15 
specific. Furthermore, some studies included regimens which are currently no longer in use, such as 16 
ifosfamide 5 g/m2 as a 24-hour infusion and doxorubicin/ifosfamide combinations with lower doses 17 
than currently used. Ideally the results of this study should be validated in a prospective observational 18 
study, comparing the overall survival in these three subgroups under the current treatments available. 19 
The results of this study are important for daily practice, because current treatment regimens 20 
are based on phase III studies currently not accounting for these differences and thereby introducing 21 
bias, as these studies suggest that included LAD patients are comparable to patients with both locally 22 
advanced and distant metastatic disease. Second, the prognosis is essential information for patients 23 
when considering palliative treatment and the differences in prognosis between patients with LAD, DM 24 
and both should be used in this decision. 25 
In conclusion, this study shows a difference in prognosis between patients with LAD, DM and 26 
patients with both LAD and DM. This study does indicate that there are a number of differences in 27 
prognostic factors between patients with LAD, DM and with both LAD and DM. Thus, in future trials the 28 
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Article tables and figures 1 















 N (%) N (%) N (%) N (%) 
Gender                                                                                                                                                                                                                                                                                                            0.002
 Male                          143 (43.5)                                                                                         565 (47.0)                                                                                         500 (53.1)                                                   1208 (48.8)                                                      
 Female                        186 (56.5)                                                                                         637 (53.0)                                                                                         442 (46.9)                                                   1265 (51.2)                                                      
Performance status                                                                                                                                                                                                                                                                                                <0.001 
 PS 0                          132 (40.1)                                                                                         635 (52.8)                                                                                         390 (41.4)                                                   1157 (46.8)                                                      
 PS 1                          155 (47.1)                                                                                         515 (42.8)                                                                                         476 (50.5)                                                   1146 (46.3)                                                      
 PS 2+                          38 (11.6)                                                                                            50 (4.2)                                                                                    74 (7.9)                                                   162 (6.6)                                                     
 Unknown                         4 (1.2)                                                                                          2 (0.2)                                                                                          2 (0.2)                                                8 (0.3)                              
Age (years)                                                                                                                                                                                                                                                                                                          0.387
 < 40 yrs                       78 (23.7)                                                                                         257 (21.4)                             216 (22.9)                                                      551 (22.3)                                   
 40-50 yrs                      66 (20.1)                                                                                         278 (23.1)                             210 (22.3)                                                          554 (22.4)                                   
 50-60 yrs                      85 (25.8)                                                                                         360 (30.0)                             274 (29.1)                                                          719 (29.1)                                   
 >=60 yrs                       95 (28.9)                                                                                         285 (23.7)                             230 (24.4)                                                          610 (24.7)                                   
 Median                                                                                                                                                                                                  52 51 51              51 0.949a
 Range                                                                                                                                                                                                   16 - 79 17 - 84        10 - 88 10 - 88
 Q1-Q3                                                                                                                                                                                                   40 - 61   42 – 60   41 - 60        41 - 60
 Unknown                         5 (1.5)                                                                                             22 (1.8)                           12 (1.3)                                                 39 (1.6)                                                    
Prior radiotherapy                                                                                                                                                                                                                                                                                                                   <0.001
 No                                 274 (83.3)                                                                                         590 (49.1)                                                                                         690 (73.2)                                               1554 (62.8)                                                      
 Yes                                 33 (10.0)                                                                                         464 (38.6)                             170 (18.0)                                                      667 (27.0)                                                
 Unknown                             22 (6.7)                                                                                          148 (12.3)                              82 (8.7)                          252 (10.2)                                                                         
Prior Surgery                                                                                                                                                                                                                                                                                                          <0.001
 No surgery                          53 (16.1)                                                                                            16 (1.3)                                                                                    161 (17.1)                                                 230 (9.3)                                            
 Non-optimal surgery                 91 (27.7)                                                                                         106 (8.8)                             184 (19.5)                                                     381 (15.4)                                        
 Complete surgery                    68 (20.7)                                                                                         487 (40.5)                             178 (18.9)                                                          733 (29.6)                                   
 Unknown                            117 (35.6)                                                                                         593 (49.3)                                                                                         419 (44.5)                                                   1129 (45.7)                                                      
histology                                                                                                                                                                                                                                                                                                                                             <0.001
 Leiomyosarcoma                                                             85 (25.8)                                                                                         412 (34.3)                             281 (29.8)                                                          778 (31.5)                                   
 Synovial sarcoma                                                         23 (7.0)                                                                                          160 (13.3)                              77 (8.2)                          260 (10.5)                                                                         
 Liposarcoma                                                             48 (14.6)                                                                                         114 (9.5)                           87 (9.2)                          249 (10.1)                                                                                       
 Other                                                         173 (52.6)                                                                                         516 (42.9)                                                                                         497 (52.8)                                                   1186 (48.0)                                                      

















 N (%) N (%) N (%) N (%) 
 GRADE I                                                          36 (10.9)                                                                                            97 (8.1)                                                                                    68 (7.2)                                                   201 (8.1)                                                     
 GRADE II                                                      86 (26.1)                                                                                         345 (28.7)                             261 (27.7)                                                          692 (28.0)                                   
 GRADE III                                                       104 (31.6)                                                                                         436 (36.3)                                                                                         315 (33.4)                                                   855 (34.6)                            
 Unknown                                                       103 (31.3)                                                                                         324 (27.0)                                                                                         298 (31.6)                                               725 (29.3)                            
Site of primary tumour                                                                                                                                                                                                                                                                                                                               <0.001
 Other                                                         222 (67.5)                                                                                         501 (41.7)                                                                                         540 (57.3)                                               1263 (51.1)                                                      
 Extr                                                          37 (11.2)                                                                                         457 (38.0)                             233 (24.7)                                                      727 (29.4)                                   
 Unknown                                                       70 (21.3)                                                                                         244 (20.3)                             169 (17.9)                                                      483 (19.5)                                   
Time between the initial diagnosis of 
sarcoma and registration 
                                                                                                                                                                                                                                                                                     <0.001
 <6 mon                                                        233 (70.8)                                                                                         416 (34.6)                                                                                         650 (69.0)                                               1299 (52.5)                                                      
 6-12 mon                                                      32 (9.7)                                                                                          190 (15.8)                              80 (8.5)                          302 (12.2)                                                                         
 1-2 yrs                                                          22 (6.7)                                                                                          238 (19.8)                              82 (8.7)                          342 (13.8)                                                                         
 >=2 yrs                                                          40 (12.2)                                                                                         352 (29.3)                             118 (12.5)                                                      510 (20.6)                                   
 Median (months)                                                                                                                                                                                                  1.9 11.8 2.3 6.3 <0.001a 
 Range (months)                                                                                                                                                                                                  0.0 - 222.8        0.0 - 346.5 0.0 - 198.7     0.0 - 346.5         
 Q1-Q3 (months)                                                                                                                                                                                                  0.8 - 9.2    4.3 - 28.5       0.9 - 9.5 1.4 - 19.1
 Unknown                                                           2 (0.6)                                                                                          6 (0.5)                                                                                          12 (1.3)                            20 (0.8)                                          
Treatment                                                                                                                                                                                                                                                                                                                       
 Anthracyclines                137 (41.6)                                                                                         461 (38.4)                                                                                         369 (39.2)                                               967 (39.1)                            
 DOX+IFO                       129 (39.2)                                                                                         432 (35.9)                                                                                         394 (41.8)                                               955 (38.6)                                         
 IFO ALONE                      53 (16.1)                                                                                         206 (17.1)                             125 (13.3)                                                      384 (15.5)                                                
 Other                          10 (3.0)                                                                                          103 (8.6)                              54 (5.7)                            167 (6.8)                                                                
Primary site involved                                                                                                                                                                                                                                                                                      
 No                       0 (0.0)                                                                                          1202 (100.0)                                                     0 (0.0)                                                    1202 (48.6)                              
 Yes                    329 (100.0)                                                                                            0 (0.0)                           942 (100.0)                            1271 (51.4)                                               
Lung metastases                                                                                                                                                                                                                                                                                                          
 No                     329 (100.0)                                                                                        316 (26.3)                                                                                       361 (38.3)                                               1006 (40.7)                                                      
 Yes                      0 (0.0)                                                                                            886 (73.7)                            581 (61.7)                                                                                    1467 (59.3)                                                      
Bone metastases                                                                                                                                                                                                                                                                                                          
 No                     329 (100.0)                                                                                         1071 (89.1)                           810 (86.0)                          2210 (89.4)                                                              
 Yes                      0 (0.0)                                                                                            131 (10.9)                            132 (14.0)                                                                                    263 (10.6)                            
Liver metastases                                                                                                                                                                                                                                                                                                         
 No                     329 (100.0)                                                                                        979 (81.4)                                                                                       745 (79.1)                                               2053 (83.0)                                                      

















 N (%) N (%) N (%) N (%) 
Other metastases                                                                                                                                                                                                                                                                                                         
 No                     329 (100.0)                                                                                        709 (59.0)                                                                                       532 (56.5)                                               1570 (63.5)                                                      
 Yes                      0 (0.0)                                                                                            493 (41.0)                            410 (43.5)                                                                                    903 (36.5)                            
Table 1 continued 1 
aKruskal-Wallis test 2 
 3 
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 N (%) N (%) N (%) N (%) 
Best overall response                                                                                                                                                                                                                                                                    
 Complete Response (CR)                      16 (4.9)                                                                                             34 (2.8)                             16 (1.7)                                                      66 (2.7)                                                      
 Partial Response (PR)                         47 (14.3)                                                                                           226 (18.8)                           133 (14.1)                          406 (16.4)                                                     
 Stable Disease (SD)                       145 (44.1)                                                                                         482 (40.1)                          362 (38.4)                                                        989 (40.0)                                                        
 Progressive Disease (PD)                       77 (23.4)                                                                                           385 (32.0)                           347 (36.8)                          809 (32.7)                                                      
 Not Evaluable                        44 (13.4)                                                                                         75 (6.2)                             84 (8.9)                          203 (8.2)                            
Responders                                                                                                                                                                                                                                                                                               
 Failure                   266 (80.9)                                                                                         942 (78.4)                          793 (84.2)                                                        2001 (80.9)                            
 Responders (CR+PR)                63 (19.1)                                                                                           260 (21.6)                           149 (15.8)                          472 (19.1)                                                     
 2 
Table 3 results of univariate analysis for prognostic factors for overall survival 3 
Overall Survival – stratified by treatment 
 















PS 0  1.00                 
<0.001 (df=2) 
1.00                 <0.001 (df=2)                                       
                                                   
1.00                 <0.001 (df=2)                                       
                                                   PS 1  1.62 (1.21, 2.17)    1.60 (1.39, 1.83)    1.49 (1.28, 1.74)    
 PS 2+ 2.38 (1.55, 3.65)     3.37 (2.46, 4.61)                                                       1.91 (1.45, 2.50)                                                       
Gender 
Male  1.00                                0.712                                              
                                                   
1.00                         0.387                                              
                                                   
1.00                                0.125                                             
                                                   Female  1.05 (0.80, 1.38)                   0.94 (0.83, 1.08)                   0.89 (0.77, 1.03)                   
Age 
< 40 yrs                    1.00                 0.030 (df=3)                                       1.00                 0.206 (df=3)                                       1.00                 0.028 (df=3)                                       
40-50 yrs                   1.36 (0.90, 2.04)                                                       1.13 (0.93, 1.37)                                                    1.04 (0.84, 1.28)                                                       
50-60 yrs                   1.40 (0.94, 2.06)                                                       1.19 (0.99, 1.42)                                                    1.31 (1.08, 1.60)                                                       
>=60 yrs                    1.77 (1.21, 2.59)                                                       1.22 (1.00, 1.49)                                                    1.15 (0.93, 1.42)                                                       
Histological 
 cell type 
Leiomyosarcoma  1.00                 0.005 (df=3)                                       1.00                 0.004 (df=3)                                       1.00                 0.043 (df=3)                                       
Synovial 0.55 (0.30, 1.00)                                                       0.82 (0.66, 1.00)                                                    0.83 (0.63, 1.11)                                                       
Liposarcoma  0.51 (0.31, 0.84)                                                       0.66 (0.52, 0.85)                                                    0.66 (0.49, 0.89)                                                       
Other  1.03 (0.76, 1.41)                                                       0.96 (0.83, 1.12)                                                    0.91 (0.78, 1.07)                                                       
Grade 
Grade I  1.00                 0.071 (df=3)                                       1.00                 0.004 (df=3)                                       1.00                 <0.001 (df=3)                                       
Grade II  1.25 (0.77, 2.02)                                                       1.33 (1.02, 1.73)                                                    1.34 (0.99, 1.82)                                                       
Grade III  1.71 (1.08, 2.70)                                                       1.55 (1.19, 2.00)                                                    1.87 (1.38, 2.53)                                                       
 Unknown 1.61 (1.00, 2.57)                                                       1.52 (1.16, 2.00)                                                    1.59 (1.17, 2.16)                                                       
Tumour site 
Other  1.00                 
0.001 (df=2) 
1.00                 0.131 (df=2)                                       
                                                   
1.00                 0.085 (df=2)                                       
                                                   Extr  0.41 (0.25, 0.67)    0.87 (0.75, 1.01)    0.82 (0.69, 0.98)    
 Unknown 1.05 (0.75, 1.48)     0.87 (0.73, 1.05)                                                       0.95 (0.78, 1.16)                                                       
Time since initial 
diagnosis 
<6 mon   1.00                 0.002 (df=3)                                       1.00                 <0.001 (df=3)                                       1.00                 0.002 (df=3)                                       
6-12 mon 2.05 (1.34, 3.16)                                                       1.05 (0.86, 1.27)                                                    1.05 (0.81, 1.36)                                                       
1-2 yrs  1.21 (0.71, 2.08)                                                       0.84 (0.70, 1.01)                                                    1.02 (0.79, 1.31)                                                       




 Table 4 Multivariate analysis for prognostic factors for overall survival  1 
 
 











Performance status PS 0 1.00 1.00 1.00 
 PS 1 1.71 (1.27, 2.31) 1.62 (1.41, 1.86) 1.44 (1.24, 1.69) 
 PS 2+ 2.40 (1.51, 3.81) 3.52 (2.56, 4.84) 1.77 (1.33, 2.34) 
  P<0.001 (df=2) P <0.001 (df=2) P <0.001 (df=2) 
Histology Leio 1.00 1.00  
 Lipo 0.62 (0.37, 1.04) 0.64 (0.50, 0.83)  
 Other 1.17 (0.85, 1.62) 0.95 (0.81, 1.10)  
 Synov 0.76 (0.41, 1.42) 0.82 (0.66, 1.00)  
  P =0.047 (df=3) P =0.003 (df=3)  
Site of tumour Other 1.00  1.00 
 Extr 0.40 (0.24, 0.66)  0.77 (0.65, 0.92) 
 Unknown 0.78 (0.54, 1.12)  0.90 (0.73, 1.10) 
  P =0.001 (df=2)  P =0.016 (df=2) 
Time since initial 
diagnosis 
<6 mon 1.00 1.00 1.00 
 6-12 mon 2.03 (1.31, 3.14) 1.16 (0.95, 1.41) 1.09 (0.84, 1.42) 
 1-2 yrs 1.56 (0.89, 2.74) 0.91 (0.76, 1.10) 0.95 (0.74, 1.23) 
 >=2 yrs 0.90 (0.57, 1.42) 0.69 (0.58, 0.82) 0.67 (0.53, 0.85) 
  P =0.006 (df=3) P <0.001 (df=3) P =0.008 (df=3) 
Gender Male   1.00 
 Female   0.84 (0.72, 0.97) 
    P =0.019 (df=1) 
Age < 40 yrs   1.00 
 40-50 yrs   1.05 (0.85, 1.31) 
 50-60 yrs   1.44 (1.18, 1.77) 
 >=60 yrs   1.17 (0.94, 1.46) 
    P =0.002 (df=3) 
Histologic grade Grade I   1.00 
 Grade II   1.32 (0.97, 1.80) 
 Grade III   1.76 (1.30, 2.39) 
 Unknown   1.45 (1.06, 1.98) 
    P <.001 (df=3) 




Table 5 Univariate analysis for prognostic factors for progression free survival 2 
Progression free survival – stratified by treatment 
 















PS 0  1.00                 
<0.001 (df=2) 
1.00                 
<0.001 (df=2) 
1.00                 0.006 (df=2)                                       
                                                   PS 1  1.39 (1.07, 1.80)    1.26 (1.12, 1.43)    1.23 (1.07, 1.42)    
 PS 2+ 2.14 (1.44, 3.17)     1.83 (1.35, 2.48)     1.34 (1.03, 1.74)                                                       
Gender 
Male  1.00                                0.510                                              
                                                   
1.00                         0.999                                              
                                                   
1.00                                0.471                                             
                                                   Female  0.92 (0.72, 1.18)                   1.00 (0.89, 1.12)                   0.95 (0.83, 1.09)                   
Age < 40 yrs                    1.00                 0.197 (df=3)                                       1.00                 0.273 (df=3)                                       1.00                 0.045 (df=3)                                       
 40-50 yrs                   1.26 (0.87, 1.82)                                                       1.12 (0.94, 1.33)                                                    1.06 (0.87, 1.29)                                                       
 50-60 yrs                   1.39 (0.98, 1.96)                                                       1.11 (0.94, 1.32)                                                    1.28 (1.06, 1.55)                                                       
 >=60 yrs                    1.40 (1.00, 1.97)                                                       1.20 (1.00, 1.43)                                                    1.19 (0.97, 1.46)                                                       
Histological 
 cell type 
Leiomyosarcoma  1.00                 0.047 (df=3)                                       1.00                 0.001 (df=3)                                       1.00                 0.013 (df=3)                                       
Synovial 0.60 (0.35, 1.01)                                                       0.75 (0.63, 0.91)                                                    0.70 (0.54, 0.91)                                                       
Liposarcoma  0.99 (0.66, 1.49)                                                       0.68 (0.55, 0.84)                                                    0.73 (0.57, 0.94)                                                       
Other  1.18 (0.88, 1.59)                                                       0.86 (0.75, 0.99)                                                    0.87 (0.75, 1.01)                                                       
grade 
Grade I  1.00                 0.798 (df=3)                                       1.00                 0.165 (df=3)                                       1.00                 0.014 (df=3)                                       
Grade II  1.10 (0.72, 1.68)                                                       1.17 (0.93, 1.48)                                                    1.31 (0.99, 1.72)                                                       
Grade III  1.20 (0.79, 1.81)                                                       1.27 (1.01, 1.60)                                                    1.53 (1.16, 2.01)                                                       
 Unknown 1.20 (0.79, 1.83)                                                       1.26 (0.99, 1.59)                                                    1.43 (1.08, 1.89)                                                       
Tumour site 
Other  1.00                 0.076 (df=2)                                       
                                                   
1.00                 0.006                                              
                                                   
1.00                 0.642 (df=2)                                       
                                                   Extr  0.66 (0.44, 0.99)    0.81 (0.71, 0.92)    0.93 (0.79, 1.09)    
 Unknown 1.10 (0.81, 1.50)                                                       0.91 (0.77, 1.07)  0.99 (0.82, 1.19)                                                       
Time since initial 
diagnosis 
<6 mon   1.00                 0.001 (df=3)                                       1.00                 <0.001 (df=3)                                       1.00                 0.153 (df=3)                                       
6-12 mon 2.10 (1.41, 3.14)                                                       1.05 (0.88, 1.25)                                                    1.08 (0.85, 1.37)                                                       
1-2 yrs  1.78 (1.09, 2.89)                                                       0.96 (0.81, 1.13)                                                    1.23 (0.97, 1.55)                                                       
>=2 yrs  1.08 (0.74, 1.58)                                                       0.70 (0.61, 0.82)                                                    0.88 (0.72, 1.08)                                                       
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Table 6 Multivariate analysis for prognostic factors for progression free survival  1 
 
 











Performance status PS 0 1.00 1.00 1.00 
 PS 1 1.43 (1.10, 1.87) 1.28 (1.13, 1.45) 1.20 (1.04, 1.39) 
 PS 2+ 2.11 (1.41, 3.17) 1.90 (1.40, 2.57) 1.24 (0.95, 1.62) 
  P <.001 (df=2) P <.001 (df=2) P =0.031 (df=2) 
Histology Leio  1.00 1.00 
 Lipo  0.69 (0.55, 0.85) 0.77 (0.60, 1.00) 
 Other  0.86 (0.75, 0.99) 0.85 (0.73, 0.99) 
 Synov  0.77 (0.64, 0.93) 0.70 (0.54, 0.92) 
   P =0.002 (df=3) P =0.024 (df=3) 
Time since initial 
diagnosis 
<6 mon 1.00 1.00  
 6-12 mon 1.92 (1.28, 2.88) 1.11 (0.93, 1.33)  
 1-2 yrs 2.07 (1.26, 3.39) 1.01 (0.85, 1.19)  
 >=2 yrs 1.08 (0.74, 1.58) 0.74 (0.64, 0.87)  
  P =0.001 (df=3) P <.001 (df=3)  
Histologic grade Grade I   1.00 
 Grade II   1.31 (0.99, 1.73) 
 Grade III   1.50 (1.14, 1.98) 
 Unknown   1.41 (1.07, 1.87) 
    P =0.029 (df=3) 
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Table 7 Univariate analysis for prognostic factors for overall response rate (a lower odds ratio 1 
indicates a higher change for good response) 2 
Response rate – stratified by treatment 
 
Locally advanced tumour Metastases only Both 
Odds Ratio 
(95% CI) P-Value 
Odds Ratio 
(95% CI) P-Value 
Odds Ratio 
(95% CI) P-Value 
Performance  
Status 
PS 0  1.00                          0.161 (df=2)               
                           
1.00                          0.801 (df=2)               
                           
1.00                          0.572 (df=2)               
                           PS 1  0.73 (0.40, 1.32)             1.07 (0.79, 1.43)             0.83 (0.57, 1.21)             
 PS 2+ 2.02 (0.65, 6.29)                                        1.24 (0.60, 2.56)                                        0.79 (0.40, 1.55)                                        
Gender 
Male  1.00                          0.856 (df=1)               
                           
1.00                          0.053 (df=1)               
                           
1.00                          0.225 (df=1)               
                           Female  1.05 (0.60, 1.86)             1.32 (1.00, 1.76)             0.80 (0.56, 1.15)             
Age 
< 40 yrs                    1.00                          0.445 (df=3)               1.00                          0.137 (df=3)               1.00                          0.043 (df=3)               
40-50 yrs                   1.33 (0.60, 2.95)                                        1.44 (0.96, 2.16)                                        0.79 (0.49, 1.27)                                        
50-60 yrs                   1.79 (0.81, 3.92)                                        1.39 (0.95, 2.04)                                        1.58 (0.95, 2.62)                                        
>=60 yrs                    1.66 (0.78, 3.54)                                        1.59 (1.04, 2.43)                                        1.26 (0.74, 2.16)                                        
Histological 
 cell type 
Leiomyosarcoma  1.00                          0.289 (df=3)               1.00                          <0.001 (df=3)               1.00                          0.772 (df=3)               
Synovial 0.41 (0.14, 1.14)                            0.42 (0.27, 0.66)                                        0.78 (0.39, 1.56)                                        
Liposarcoma  1.20 (0.42, 3.40)                                        0.32 (0.20, 0.53)                                        0.77 (0.39, 1.51)                                        
Other  0.84 (0.42, 1.67)                                        0.67 (0.47, 0.96)                                        0.83 (0.54, 1.25)                                        
Grade 
Grade I  1.00                          0.418 (df=3)               1.00                          0.180 (df=3)               1.00                          0.022 (df=3)               
Grade II  1.30 (0.43, 3.90)                                        1.27 (0.71, 2.24)                                        1.93 (0.90, 4.12)                                        
Grade III  0.67 (0.25, 1.81)                                        0.87 (0.50, 1.50)                                        0.87 (0.44, 1.75)                                        
 Unknown 0.85 (0.31, 2.37)                                        1.14 (0.64, 2.04)                                        1.10 (0.54, 2.23)                                        
Tumour site 
Other  1.00                          0.597 (df=2)               1.00                          <0.001 (df=2)               1.00                          0.742 (df=2)               
Extr  0.84 (0.36, 2.00)             0.44 (0.31, 0.60)             0.98 (0.63, 1.51)             
 Unknown 0.71 (0.36, 1.40)                                        0.78 (0.52, 1.18)                                        0.83 (0.52, 1.33)                                        
Time since initial 
diagnosis 
<6 mon   1.00                          0.180 (df=3)               1.00                          0.447 (df=3)               1.00                          0.510 (df=3)               
6-12 mon 1.90 (0.63, 5.70)                                        1.42 (0.91, 2.22)                                        0.88 (0.47, 1.63)                                        
1-2 yrs  1.67 (0.47, 5.98)                                       1.21 (0.81, 1.80)                                        0.76 (0.42, 1.37)                                        
>=2 yrs  3.23 (0.95, 10.96)                                       1.12 (0.79, 1.60)                                        1.40 (0.73, 2.66)                                        
 3 




Tables 8a Multivariate analysis for overall response rate for metastatic disease only (a lower 2 
odds ratio indicates a higher change for good response) 3 
Parameter Levels 
Odds Ratio 
(95% CI) P-value 
Histology                   Leio  1.00                          0.002 (df=3)               
                               Lipo  0.40 (0.24, 0.66)                                        
                               Other 0.80 (0.56, 1.16)                                        
                               Synov 0.58 (0.36, 0.93)                                        
Site of tumour Other 1.00                          0.001 (df=2)               
                               Extr  0.51 (0.36, 0.73)                                        
                               Unknown   0.80 (0.53, 1.22)                                        
 4 
Tables 8b Multivariate analysis for overall response rate for patients with both locally advanced 5 
and metastatic disease (a lower odds ratio indicates a higher change for good response) 6 
Parameter Levels 
Odds Ratio 
(95% CI) P-value 
Grade                   GRADE I   1.00                          0.022 (df=3)               
                               GRADE II  1.93 (0.90, 4.12)                                        
                               GRADE III 0.87 (0.44, 1.75)                                        
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Supplementary table 1 Included studies and study treatments 




Total = 2473 
1. EORTC 
62761 R. Ph II CYVADIC FU (191)




62801 R. Ph II/III DOX 75 (106) EPI 75 (104)  
184 
3. EORTC 
62842 Ph II 
DOX 50 + IFO 5000 
(203)   
189 
4. EORTC 
62851 R. Ph III DOX 75 (295) 






62883 Ph II 
DOX 75 + IFO 5000 
(111)#   
- 
6. EORTC 
62901 R. Ph II/III DOX 75 (112)
 # EPI 3*50 (111) # EPI 1*150 (111) # - 
7. EORTC 
62903  R. Ph III 
DOX 50 + IFO 5000 
(157) 




62912 R. ph II IFO 5000 (93) IFO 3*3000 (89)  
100 
9. EORTC 





62953 Ph II IFO 12 (124)   
91 
11. EORTC 
62962 R. Ph II DOX 75 (45) Caelyx (50)  
88 
12. EORTC 
62971 R. Ph III DOX 75 (110) IFO 3*3000 (109) IFO 5000 (107) 
292 
13. EORTC 
62012 R. Ph III DOX 75 (228) 




62061 R. Ph II DOX 75 (39) Brostallicin (N=79)  
116 
15. EORTC 
62091 R. Ph II DOX 75 (43) 
Trabectedin  3hrs 
(N=47)  
Trabectedin  
24hrs (N=43)  
133 
 
R. randomized, Ph phase, CYVADIC cyclophosphamide, vincristine, doxorubicin, dacarbazin, DOX doxorubicin, EPI epirubicin, 
IFO ifosfamide, given dose is in mg/m2 





Supplementary table 2 Inclusion per year 
YEAR Protocol 
Freque
ncy 62012 62061 62091 62801 62842 62851 62903 62912 62941 62953 62962 62971 Total 
1980 0 0 0 4 0 0 0 0 0 0 0 0 4 
1981 0 0 0 84 0 0 0 0 0 0 0 0 84 
1982 0 0 0 72 0 0 0 0 0 0 0 0 72 
1983 0 0 0 24 0 0 0 0 0 0 0 0 24 
1984 0 0 0 0 74 0 0 0 0 0 0 0 74 
1985 0 0 0 0 114 11 0 0 0 0 0 0 125 
1986 0 0 0 0 1 123 0 0 0 0 0 0 124 
1987 0 0 0 0 0 122 0 0 0 0 0 0 122 
1988 0 0 0 0 0 146 0 0 0 0 0 0 146 
1989 0 0 0 0 0 95 0 0 0 0 0 0 95 
1990 0 0 0 0 0 15 0 0 0 0 0 0 15 
1992 0 0 0 0 0 0 48 0 0 0 0 0 48 
1993 0 0 0 0 0 0 123 0 0 0 0 0 123 
1994 0 0 0 0 0 0 105 13 0 0 0 0 118 
1995 0 0 0 0 0 0 17 66 24 0 0 0 107 
1996 0 0 0 0 0 0 0 21 16 28 0 0 65 
1997 0 0 0 0 0 0 0 0 0 63 40 0 103 
1998 0 0 0 0 0 0 0 0 0 0 48 49 97 
1999 0 0 0 0 0 0 0 0 0 0 0 106 106 
2000 0 0 0 0 0 0 0 0 0 0 0 86 86 
2001 0 0 0 0 0 0 0 0 0 0 0 51 51 
2003 10 0 0 0 0 0 0 0 0 0 0 0 10 
2004 55 0 0 0 0 0 0 0 0 0 0 0 55 
2005 68 0 0 0 0 0 0 0 0 0 0 0 68 
2006 63 3 0 0 0 0 0 0 0 0 0 0 66 
2007 59 71 0 0 0 0 0 0 0 0 0 0 130 
2008 63 42 0 0 0 0 0 0 0 0 0 0 105 
2009 86 0 0 0 0 0 0 0 0 0 0 0 86 
2010 31 0 0 0 0 0 0 0 0 0 0 0 31 
2011 0 0 27 0 0 0 0 0 0 0 0 0 27 
2012 0 0 106 0 0 0 0 0 0 0 0 0 106 



















 N (%) N (%) N (%) N (%) 
Histological cell type for other                                                                                                                                                                                                                                                                          
 Malignant fibrous 
histiocytoma                   
   41 (23.7)                                                                                         124 (24.0)                       90 (18.1)                      255 (21.5)                      
 Fibrosarcoma                    12 (6.9)                                                                                          37 (7.2)                                                                                          40 (8.0)                                            89 (7.5)                     
 Rhabdomyosarcoma                   10 (5.8)                                                                                          17 (3.3)                                                                                          29 (5.8)                                            56 (4.7)                     
 Angiosarcoma                    12 (6.9)                                                                                          28 (5.4)                                                          45 (9.1)                                            85 (7.2)                              
 Neurogenic sarcomas                    25 (14.5)                                                                                         50 (9.7)                                                                                          34 (6.8)                                            109 (9.2)                      
 Miscellaneous                     47 (27.2)                                                                                         210 (40.7)                         180 (36.2)                                             437 (36.8)                     
























 N (%) N (%) N (%) N (%) 
Gender                                                                                                                                                                                                                                                                                      
 Male                           22 (44.0)                                                                                           172 (46.2)                                 129 (49.2)                              323 (47.2)                                                          
 Female                         28 (56.0)                                                                                           200 (53.8)                                 133 (50.8)                              361 (52.8)                                                          
Performance status                                                                                                                                                                                                                                                                          
 PS 0                           28 (56.0)                                                                                           225 (60.5)                                 119 (45.4)                              372 (54.4)                                                     
 PS 1                           22 (44.0)                                                                                           145 (39.0)                                 143 (54.6)                              310 (45.3)                                                      
 PS 2+                           0 (0.0)                                                                                          2 (0.5)                                          0 (0.0)                                                    2 (0.3)                                                               
Age (years)                                                                                                                                                                                                                                                                           
 < 40 yrs                       13 (26.0)                                                                                         54 (14.5)                                           49 (18.7)                                                    116 (17.0)                                                           
 40-50 yrs                       4 (8.0)                                                                                             88 (23.7)                               68 (26.0)                              160 (23.4)                                                           
 50-60 yrs                      19 (38.0)                                                                                           131 (35.2)                               85 (32.4)                                                           235 (34.4)                                  
 >=60 yrs                       14 (28.0)                                                                                         99 (26.6)                                           60 (22.9)                                                    173 (25.3)                                                           
 Median                                                                                                                                                                                                  54 54               51 53               
 Range                                                                                                                                                                                                   21 - 78 18 - 84        19 - 88 18 - 88  
 Q1-Q3                                                                                                                                                                                                   36 - 60    44 - 60        43 - 59 44 - 60        
Prior radiotherapy                                                                                                                                                                                                                                                        
 No                      26 (52.0)                                                                                           110 (29.6)                                 143 (54.6)                              279 (40.8)                                                     
 Yes                      2 (4.0)                                                                                          116 (31.2)                                             38 (14.5)                              156 (22.8)                                 
 Missing                 22 (44.0)                                                                                           146 (39.2)                               81 (30.9)                                                           249 (36.4)                                
Prior Surgery                                                                                                                                                                                                                                                             
 Unknown                 50 (100.0)                                                                                          372 (100.0)                               262 (100.0)                              684 (100.0)                                                   
histology                                                                                                                                                                                                                                                                                                          
 Leiomyosarcoma                                                          10 (20.0)                                                                                           107 (28.8)                               69 (26.3)                                                              186 (27.2)                                 
 Synovial sarcoma                                                         3 (6.0)                                                                                             53 (14.2)                               23 (8.8)                               79 (11.5)                                                         
 Liposarcoma                                                             16 (32.0)                                                                                         44 (11.8)                                           37 (14.1)                                                    97 (14.2)                                                             
 Other                                                            21 (42.0)                                                                                           168 (45.2)                                 133 (50.8)                              322 (47.1)                                                     
Histopathological grade                                                                                                                                                                                                                                                                                            
 GRADE I                                                           4 (8.0)                                                                                             15 (4.0)                               12 (4.6)                              31 (4.5)                                                             
 GRADE II                                                         19 (38.0)                                                                                           123 (33.1)                               98 (37.4)                                                              240 (35.1)                                 
 GRADE III                                                        16 (32.0)                                                                                           170 (45.7)                                 113 (43.1)                              299 (43.7)                                                     
 Missing                                                          11 (22.0)                                                                                         64 (17.2)                                           39 (14.9)                                                    114 (16.7)                                                           
Site of primary tumor                                                                                                                                                                                                                                                                                              
 Other                                                            40 (80.0)                                                                                           183 (49.2)                                 183 (69.8)                              406 (59.4)                                                     
 Extr                                                             10 (20.0)                                                                                           176 (47.3)                               76 (29.0)                                                              262 (38.3)                                 
 Missing                                                           0 (0.0)                                                                                             13 (3.5)                               3 (1.1)                                                               16 (2.3)                                
Time between the initial diagnosis of sarcoma 
and registration 
                                                                                                                                                                                                                                                    
 <6 mon                                                           31 (62.0)                                                                                           121 (32.5)                                 175 (66.8)                              327 (47.8)                                                     
 6-12 mon                                                          7 (14.0)                                                                                            60 (16.1)                               21 (8.0)                              88 (12.9)                                                         
 1-2 yrs                                                           6 (12.0)                                                                                            64 (17.2)                               26 (9.9)                              96 (14.0)                                                         
 >=2 yrs                                                           6 (12.0)                                                                                         127 (34.1)                                   40 (15.3)                              173 (25.3)                                 
 Median                                                                                                                                                                                                  2.3         12.3 2.6 8.1
 Range                                                                                                                                                                                                   0.0 - 117.7 0.2 - 249.8       0.0 - 198.7 0.0 - 249.8      


















 N (%) N (%) N (%) N (%) 
Treatment                                                                                                                                                                                                                                                                        
 Anthracyclines                 25 (50.0)                                                                                           159 (42.7)                                 115 (43.9)                              299 (43.7)                                                     
 DOX+IFO                        15 (30.0)                                                                                           110 (29.6)                               93 (35.5)                                                           218 (31.9)                                
 Other                          10 (20.0)                                                                                           103 (27.7)                               54 (20.6)                                                           167 (24.4)                                  
Primary site involved                                                                                                                                                                                                                                                                
 No                       0 (0.0)                                                                                          372 (100.0)                                             0 (0.0)                                               372 (54.4)                                                    
 Yes                     50 (100.0)                                                                                            0 (0.0)                              262 (100.0)                               312 (45.6)                                                          
Lung metastases                                                                                                                                                                                                                                                           
 No                      50 (100.0)                                                                                        86 (23.1)                                                80 (30.5)                                                        216 (31.6)                                                           
 Yes                      0 (0.0)                                                                                          286 (76.9)                                      182 (69.5)                                                    468 (68.4)                                                      
Bone metastases                                                                                                                                                                                                                                                           
 No                      50 (100.0)                                                                                          323 (86.8)                               213 (81.3)                              586 (85.7)                                                     
 Yes                      0 (0.0)                                                                                             49 (13.2)                               49 (18.7)                               98 (14.3)                                                             
Liver metastases                                                                                                                                                                                                                                                                     
 No                      50 (100.0)                                                                                          300 (80.6)                               211 (80.5)                              561 (82.0)                                                          
 Yes                      0 (0.0)                                                                                             72 (19.4)                               51 (19.5)                              123 (18.0)                                                           
Other metastases                                                                                                                                                                                                                                                          
 No                      50 (100.0)                                                                                          148 (39.8)                               89 (34.0)                                                           287 (42.0)                                  
 Yes                      0 (0.0)                                                                                          224 (60.2)                                      173 (66.0)                                                    397 (58.0)                                                      
 
Post 1999 subgroup analysis: protocols 62012, 62061, 62091 
Limited subgroup (N =684) of which the majority belongs to 62012 (435) – phase 3 and two smaller 

















O N Number of patients at risk : Stage
26 50 38 29 17 13 9 8 7 7
248 372 285 172 108 79 53 33 20 19














Median (95% CI) 
(Months) 







Locally advanced        50 26 17.84 (13.80, 
39.39) 
43.0 (27.0, 58.1) 1.00                 <0.001 
(df=2)                                       
Metastases only        372        248 14.36 (12.81, 
16.26) 
33.8 (28.3, 39.3) 1.51 (1.01, 
2.27) 
                                                   
Both                    262        198 11.93 (10.51, 
13.47)            
20.6 (15.3, 26.5) 1.99 (1.32, 
3.01) 












Median (95% CI) 
(Months) 







Locally advanced        50        44 7.85 (5.29, 11.24) 34.9 (22.0, 48.1) 1.00                 0.002 (df=2)                                       
Metastases only        372       362 4.78 (3.91, 5.59) 14.8 (11.4, 18.6) 1.65 (1.20, 
2.28) 
                                                   
Both                    262        250 4.27 (2.89, 5.52) 12.4 (8.7, 16.8) 1.79 (1.29, 
2.48) 
















O N Number of patients at risk : Disease stage
44 50 29 17 10 7 5
362 372 157 55 28 17 10




















 N (%) N (%) N (%) 
Best overall response                                                                                                                                                                                                                                                       
 Complete Response (CR)                      0 (0.0) 6 (1.6)                                                                                             1 (0.4)                       
 Partial Response (PR)                         4 (8.0)                                                                                           77 (20.7)                       30 (11.5)                                                                                         
 Stable Disease (SD)                     31 (62.0)                                                                                         159 (42.7)                                                                                         125 (47.7)                                           
 Progressive Disease (PD)                         11 (22.0)                                                                                           116 (31.2)                      84 (32.1)                                                                                         
 Not Evaluable                        4 (8.0)                                                                                         14 (3.8)                                                                                          22 (8.4)                                            
Responders                                                                                                                                                                                                                                                                  
 Failure                   46 (92.0)                                                                                         289 (77.7)                                                                                         231 (88.2)                                           




- Very low power in locally advanced subgroup with only N=50 
 




(95% CI) P-value 
Performance status             PS 0     1.00                          <.001
(df=2)             
                               PS 1     1.84 (1.42, 2.39)                                      
                               PS 2+    9.52 (2.24, 40.47)                                     
Time since initial diagnosis <6 mon   1.00                          <.001
(df=3)             
                               6-12 mon 0.58 (0.40, 0.86)                                      
                               1-2 yrs  0.59 (0.40, 0.86)                                      
                               >=2 yrs  0.44 (0.32, 0.61)                                      
Gender                         Male     1.00                          0.034
(df=1)             









(95% CI) P-value 
Performance 
status             
PS 0  1.00                          0.002
(df=1)             
                               PS 1  1.57 (1.18, 2.09)                                      
                                  
 




(95% CI) P-value 
Performance status             PS 0     1.00                          <.001
(df=2)             
                               PS 1     1.51 (1.21, 1.87)                                      
                               PS 2+    3.22 (0.78, 13.19)                                     
Time since initial 
diagnosis 
<6 mon   1.00                          <.001
(df=3)             
                               6-12 mon 0.73 (0.53, 1.00)                                      
                               1-2 yrs  0.66 (0.48, 0.90)                                      
                               >=2 yrs  0.51 (0.39, 0.66)                                      
 




(95% CI) P-value 
Grade                        GRADE I   1.00                          0.050
(df=3)             
                               GRADE II  1.21 (0.66, 2.22)                                      
                               GRADE III 1.72 (0.94, 3.15)                                      









(95% CI) P-value 
histology                         Leio      1.00                          0.001
(df=3)               
                               Lipo      0.26 (0.11, 0.62)                                        
                               Other     1.36 (0.66, 2.81)                                        
                               Synov     1.03 (0.40, 2.62)                                        
Site of tumor                       Other     1.00                          0.001
(df=2)               
                               Extr      0.31 (0.16, 0.59)                                        
                               Unknown       0.21 (0.05, 0.87)                                        
Grade                        GRADE I   1.00                          0.013
(df=3)               
                               GRADE II  3.35 (0.90, 12.51)                                       
                               GRADE III 2.20 (0.60, 8.07)                                        
                               Unknown   0.66 (0.15, 2.80)                                        
SEX                            Male      1.00                          0.045
(df=1)               
                               Female    0.56 (0.32, 0.99)                                        
 
Response rate – both:  
None significant 
 
